Pharma BD Deal Intelligence

Sanofi SA / Regeneron Pharmaceuticals, Inc.

2015 · Co-Development · $2.2B · Complete

Positive — critic reaction at announcement

CALLED IT — OFF BY 6

Sanofi and Regeneron launched a major immuno-oncology collaboration in 2015, with Sanofi committing up to $2.17B including $640M in upfront payments. This expanded their long-standing antibody alliance that originated in 2003 and had produced Dupixent (dupilumab), Praluent (alirocumab), and other antibody therapeutics. The I-O collaboration was later restructured in 2019 when Sanofi paid $462M to exit.

Key facts

Announced Jul 28, 2015
Closed Jul 28, 2015
Deal value $2.2B
Deal type Co-Development
Therapeutic area Cardiovascular, Dermatology, Immunology, Metabolic, Oncology
Indications Atopic Dermatitis, Hypercholesterolemia, Various Cancers
Key assets Dupixent (dupilumab), Praluent (alirocumab), cemiplimab (PD-1 inhibitor), Regeneron VelociSuite antibody platform
Mechanism IL-4/IL-13 dual inhibitor, PCSK9 inhibitor, PD-1 inhibitor

Related deals — scored

Deal	Year	Value	Outcome
Sanofi SA / Regeneron Pharmaceuticals, Inc. (this deal)	2015	$2.2B	57
Sanofi SA / Regeneron Pharmaceuticals, Inc.	2007	$1.0B	97
Sanofi SA / Synthelabo S.A.	1998	$11.0B	84
Sanofi SA / Genzyme Corporation	2011	$20.1B	84
Sanofi SA / Amunix Pharmaceuticals Inc.	2021	$1.2B	76
Sanofi SA / Genzyme Corporation	2010	$18.5B	75
Sanofi SA / Translate Bio Inc.	2018	$805M	73

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2015 deals · Sanofi SA deals · Cardiovascular deals